NEW YORK, April 19, 2017 /PRNewswire/ --
Stock-Callers.com today has initiated reports coverage on Gilead Sciences Inc. (NASDAQ: GILD), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Mast Therapeutics Inc. (NYSEMKT: MSTX), and Novavax Inc. (NASDAQ: NVAX). These companies belong to the Biotech industry, which serves the medical, agricultural, environmental, and industrial markets. Biotech firms differ from conventional drug makers in that they utilize natural ingredients, as opposed to synthetic ones. Learn more about these stocks by downloading their comprehensive and free reports at:
On Tuesday, shares in Foster City, California headquartered Gilead Sciences Inc. saw a slight decline of 0.96%, ending the day at $66.06. The stock recorded a trading volume of 7.36 million shares. The Company's shares are trading below their 50-day moving average by 3.06%. Moreover, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and Middle-East, have a Relative Strength Index (RSI) of 35.98.
On April 07th, 2017, Gilead Sciences announced that the US FDA has approved supplemental indications for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) tablets and Sovaldi® (sofosbuvir 400 mg) tablets for the treatment of chronic hepatitis C virus infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg. GILD complete research report is just a click away and free at:
Shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. ended the day 1.64% higher at $6.80 with a total trading volume of 2.46 million shares. In the previous three months and on an YTD basis, the stock has surged 188.14% and 223.81%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 14.35% and 85.46%, respectively. Furthermore, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have an RSI of 50.08.
On April 11th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $14 per share.
On April 17th, 2017, Aurinia Pharma announced that it has signed a Definitive Agreement granting Merck Animal Health, known as MSD Animal Health outside of the US and Canada, worldwide rights to develop and commercialize Aurinia's patented nanomicellar voclosporin ophthalmic solution for the treatment of dry eye syndrome in dogs. The complimentary report on AUPH can be downloaded at:
At the close of trading on Tuesday, shares in San Diego, California headquartered Mast Therapeutics Inc. finished 5.50% lower at $0.13 with a total trading volume of 4.63 million shares. The stock has advanced 30.50% in the last one month and 45.00% on an YTD basis. The Company's shares are trading above their 50-day moving average by 6.13%. Additionally, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have an RSI of 53.33.
On April 11th, 2017, Mast Therapeutics announced that Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC have both recommended that Mast stockholders vote "FOR" the proposed merger with Savara Inc. and the related proposals in the Company's proxy statement/prospectus/information statement for the special meeting of its stockholders to be held on April 21st, 2017 at 9:00 a.m. PT. Sign up for your complimentary research report on MSTX at:
Gaithersburg, Maryland headquartered Novavax Inc.'s shares recorded a trading volume of 6.09 million shares at the end of yesterday's session. The stock closed the day 5.74% lower at $0.83. The Company's shares are trading below their 50-day moving average by 36.36%. Additionally, shares of Novavax, which focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have an RSI of 19.05. Get free access to your research report on NVAX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA